{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:52:26Z","timestamp":1787701946076,"version":"build-2784847793"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejso.2019.10.032","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T01:42:35Z","timestamp":1572054155000},"page":"577-581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"PA","title":["Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies"],"prefix":"10.1016","volume":"46","author":[{"given":"S.P.","family":"Somashekhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Yethadka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kumar C","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.R.","family":"Ashwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabber","family":"Zaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Rauthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ejso.2019.10.032_bib1","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.10.032_bib2","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2019.10.032_bib3","first-page":"1363","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Van Driel","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ejso.2019.10.032_bib4","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","article-title":"Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality","volume":"249","author":"Chua","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2019.10.032_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: rationale and technique","volume":"2","author":"Gonzalez-Moreno","year":"2010","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.ejso.2019.10.032_bib6","series-title":"Standardization of patient selection and hyperthermic intraperitoneal chemotherapy protocol for peritoneal surface malignancy in Indian patients IJGO","author":"Somashekhar","year":"2017"},{"key":"10.1016\/j.ejso.2019.10.032_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2019.10.032_bib8","series-title":"Cancer therapy evaluation program, common Terminology Criteria for adverse Events","author":"DCTD","year":"2009"},{"key":"10.1016\/j.ejso.2019.10.032_bib9","series-title":"Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. A Manual for Physicians and Nurses","author":"Sugarbaker","year":"1998"},{"issue":"11","key":"10.1016\/j.ejso.2019.10.032_bib10","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"issue":"5","key":"10.1016\/j.ejso.2019.10.032_bib11","first-page":"243","article-title":"Management of hypomagnesemia in cancer patients receiving chemotherapy","volume":"6","author":"Saif","year":"2008","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.ejso.2019.10.032_bib12","first-page":"4265","article-title":"Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer","volume":"42","author":"Ozols","year":"1982","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejso.2019.10.032_bib13","series-title":"Peritoneal carcinomatosis: drugs and diseases","first-page":"7","article-title":"Early postoperative intraperitoneal adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma","author":"Sugarbaker","year":"1996"},{"issue":"2","key":"10.1016\/j.ejso.2019.10.032_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial","volume":"122","author":"Deraco","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.10.032_bib15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10434-999-0790-0","article-title":"Morbidity and mortality of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the Coliseum technique","volume":"6","author":"Stephens","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2019.10.032_bib16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1245\/s10434-015-4679-9","article-title":"Mitomycin C pharmacokinetics as predictor of severe neutropenia in hyperthermic intraperitoneal therapy","volume":"22","author":"Kemmel","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2019.10.032_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-010-1460-4","article-title":"Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis","volume":"68","author":"Van der Speeten","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejso.2019.10.032_bib18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1245\/ASO.2003.01.018","article-title":"Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive patients","volume":"10","author":"Glehen","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2019.10.032_bib19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jso.23228","article-title":"Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis","volume":"107","author":"Glockzin","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2019.10.032_bib20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.027","article-title":"A\u00a0multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors","volume":"226","author":"Levine","year":"2018","journal-title":"J\u00a0Am Coll Surg"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319309126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319309126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:32:41Z","timestamp":1760059961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798319309126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0748798319309126"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2019.10.032","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2019.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}